Bell Investment Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.9K Buy
478
+214
+81% +$9.19K ﹤0.01% 437
2026
Q1
$9.7K Sell
264
-89
-25% -$4.22K ﹤0.01% 689
2025
Q4
$18K Buy
353
+7
+2% +$358 ﹤0.01% 481
2025
Q3
$19.2K Sell
346
-99
-22% -$5.79K ﹤0.01% 420
2025
Q2
$30.7K Buy
445
+71
+19% +$4.83K 0.01% 320
2025
Q1
$26K Buy
374
+51
+16% +$4.21K ﹤0.01% 324
2024
Q4
$27.8K Sell
323
-41
-11% -$4.43K 0.01% 311
2024
Q3
$43.3K Sell
364
-17
-4% -$2.27K 0.01% 244
2024
Q2
$54.4K Buy
381
+63
+20% +$8.35K 0.01% 208
2024
Q1
$40.8K Buy
318
+23
+8% +$2.74K 0.01% 235
2023
Q4
$30.5K Buy
295
+9
+3% +$890 0.01% 266
2023
Q3
$26K Sell
286
-32
-10% -$2.82K 0.01% 264
2023
Q2
$25.7K Buy
318
+34
+12% +$2.78K 0.01% 260
2023
Q1
$22.6K Sell
284
-188
-40% -$13.3K 0.01% 280
2022
Q4
$31.9K Hold
472
0.01% 223
2022
Q3
$24K Hold
472
0.01% 233
2022
Q2
$26K Buy
+472
New +$26.2K 0.01% 225
2021
Q4
$43K Buy
770
+194
+34% +$10.5K 0.01% 179
2021
Q3
$28K Buy
+576
New +$27.8K 0.01% 224

Other funds holding NVO

Bell Investment Advisors's NVO Position: Q2 2026 in Review

Bell Investment Advisors increased its Novo Nordisk (NVO) stake by 81% in Q2 2026, buying an estimated $9.19K and bringing the position to 478 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #437.

Bell Investment Advisors first reported a position in NVO in Q3 2021 and has held it in 19 quarters since. The position peaked at $54.4K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Bell Investment Advisors held 478 shares of Novo Nordisk worth $22.9K as of Q2 2026.
  • Bell Investment Advisors bought 214 Novo Nordisk shares in Q2 2026, an estimated $9.19K.
  • Novo Nordisk made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #437 holding.
  • Bell Investment Advisors first reported a position in Novo Nordisk in Q3 2021 and has held it in 19 quarters since.
  • Bell Investment Advisors's Novo Nordisk position peaked at $54.4K in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.